Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its 'asset-centric' approach to investing. The new firm launches with the close of Medicxi Ventures 1 (MV1), a new €210m ($250m) fund that will continue focusing on asset-centric, early-stage investments in European life science programs.
Medicxi Ventures will be managed by four general partners: Francesco De Rubertis, David Grainger, Kevin Johnson and Michèle Ollier. The...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
